CAND1 is a conditional inhibitor for CRL2 E3s dependent on CRL2 substrate Kd. Unlike CRL1 E3s that have fast on rates, CRL2 E3s have slow on rates. Thus, instead of dictating E3 assembly repertoires for CRL2s, CAND1 enhances CRL2 substrate specificity. nature.com/articles/s4159…

GWAS and ExWAS of human hypothalamus volumes identify a strong association with ADAMTS8 (encodes an angiogenesis-inhibiting enzyme), implicated by common variants, rare variants, and eQTLs. Fascinating! Chen, You, Zhang, Wu, et al. Nat Hum Behav nature.com/articles/s4156…

Congrats to Chris Parker and team on the dev of a covalent (PPI) inhibitor of SLC15A4 — highlighting the power of chemoproteomics for IDing modulators of difficult membrane targets. Love all the attn to I&I this last year nature.com/articles/s4158…

Congrats to our chem bio grad student Margot Meyers Margot Meyers on her ACS Chem Bio paper on the discovery of a covalent DDB1 recruiter for PROTAC applications! ⁦College of Chemistry⁩ ⁦ pubs.acs.org/doi/10.1021/ac…

Congratulations Stuart Schreiber! I am very excited to see all that comes out of Arena BioWorks — a new model for drug discovery is desperately needed! nytimes.com/2024/01/12/bus…

Wonderful to have our paper, "Inherited blood cancer predisposition through altered transcription elongation", published (open access) in Cell today! cell.com/cell/fulltext/… 🧵 (1/n)

$VKTX obesity market has all the momentum. Likely suitors: - $PFE - just pulled their Ph3 trial from Danuglipron twice daily dosing due to AE’s. Wants in obesity market. - $LLY - could own the obesity market with $VKTX and tirzepatide. Has speculation interest. Approaching

Congratulations to #MolecularTherapeutics faculty Ziyang Zhang and Kevan Shokat on their wonderful paper on targeting the G12D variant of K-Ras! nature.com/articles/s4158…

Does single-cell data increase probability of success in drug discovery and clinical success? 🧐 Drug targets backed by single-cell data triple the chances of a target reaching phase III, when combined with genetic data 🎯 Read the pre-print of this brilliant study by Sanofi

$VKTX Infact $AMGN discontinuing Oral drug either due to low efficacy or Safety issues is big positive for $VKTX $AMGN Remember 50% Discontinuation rates, 60-100% Nausea at 280mg dose, 100% nausea at 420mg dose. 83% vomiting at 280mg and 75% vomiting at 420mg dose Can’t

Recent draft guidance from U.S. FDA on 'platform technology designation' would enable companies to reuse prior data for future approvals. A small step, a giant leap? We may be entering the 'reusable rocket' era for biotech... 🧬🚀 Draft document: fda.gov/media/178928/d…

Previous papers have shown that drug targets with supporting genetic evidence can have twice the success rate when reaching clinical trials. In our most recent paper (medrxiv.org/content/10.110…), we looked at how data from 23andMe can provide additional genetic evidence. 🧵1/8

$LLY buyinng $MORF $3.2B - oral integrin for inflammatory bowel disease. $57 per share. 78% premium. prnewswire.com/news-releases/…

Well we finally got an Ozempic vs. Mounjaro head-to-head (kind of)... Brief thread to break down the weight-loss-drug showdown...

Big day for the lab as our MultiMap platform is now published on Science! Congratulations to Lindsey Zhi lindsey Lin and the team! science.org/doi/10.1126/sc…

#CandidTherapeutics, led by Ken Song, launched today with $370M in funding. Vida is proud to support Candid as it develops cutting-edge therapeutic programs that address significant unmet medical needs in immunology. Learn more: bit.ly/4gbzijr #VidaPortfolio

(1/5) Excited to share this collab with the Cravatt lab at Scripps Research! A structurally diverse library of photoreactive, stereoselective chemical probes can be used for high-throughput #proteomics experiments in living systems. authors.elsevier.com/c/1k5v78jWWJxM…

New work out now CellChemicalBiology! We developed a non-degrader CIP-DEL platform for discovery of modulators of protein-protein interaction, and identified a compound that blocks caspase 3 cleavage and reverses functional defects of #IBD risk variant ATG16L1 T300A.

I think this will become much more common going forward. Pharma in-licensing IND-enabled or Phase 1 assets. Frankly, this is probably the BEST "in-house" R&D strategy

Development of an FKBP12-recruiting chemical-induced proximity DNA-encoded library and its application to discover an autophagy potentiator by Zher Yin Tan, Stuart Schreiber, Xavier Lab at Broad Institute dlvr.it/TJgZ6j